Update on the Development of SUVN‐I6107: A True Positive Allosteric Modulator of the Muscarinic M1 Acetylcholine Receptor for the Treatment of Dementia
Results from the non-clinical studies suggest SUVN-I6107 may have memory enhancing property in various forms of dementias. SUVN-I6107 is currently being studied in a Phase-1 study (NCT06705088) to evaluate its safety, tolerability, pharmacokinetics, and pharmacodynamic effects after single and repeated administrations in healthy human subjects.
Authors
- Vijay Benade
- Mohammed Abdul Rasheed (ORCID: https://orcid.org/0000-0002-6417-2552)
- Ramakrishna Nirogi (ORCID: https://orcid.org/0000-0002-2045-0784)
- Rajesh Kumar Badange
- Rajesh Babu Medapati
- Venkatesh Goura
- Surendra Petlu
- Veera Raghava Chowdary Palacharla (ORCID: https://orcid.org/0000-0001-7493-4920)
- Rajesh Kallepalli
- Anil Shinde
- Ramkumar Subramanian
- Renny Abraham
- Santosh Kumar Pandey
- Vinod Kumar Goyal
Institutions
- Suven Life Sciences (India) (IN)
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1002/alz70856_099660
- Primary Topic
- Receptor Mechanisms and Signaling
- Type
- article
- Field-Weighted Citation Impact
- 0.00